PD19-09 PATHOLOGIC UPGRADING IN FAVORABLE INTERMEDIATE RISK ACTIVE SURVEILLANCE PATIENTS: CLINICAL HETEROGENEITY AND IMPLICATIONS FOR ACTIVE SURVEILLANCE DECISION

INTRODUCTION AND OBJECTIVE:Current guidelines support active surveillance (AS) for select patients with favorable intermediate risk (FIR) prostate cancer (PCa). A significant proportion of FIR PCa ...